On July 30, 2025, Moderna announced that the European Commission (EC) granted marketing authorization for the updated formulation of Moderna’s COVID-19 vaccine Spikevax®. The updated vaccine targets the LP.8.1 variant of...more
8/19/2025
/ Biotechnology ,
Coronavirus/COVID-19 ,
European Commission ,
European Medicines Agency (EMA) ,
Life Sciences ,
Marketing Authorization Application ,
Moderna Inc. ,
Pharmaceutical Industry ,
Prescription Drugs ,
Public Health ,
Vaccinations
On May 27, 2025, Fresenius Kabi (“Fresenius”) announced that the EMA’s Committee for Medicinal Products for Human Use (“CHMP”) had issued positive opinions for Fresenius’s two denosumab biosimilar candidates....more
The European Medicines Agency’s (EMA) Committee for Medicinal Use Products (CHMP) recently recommended approval of six new biosimilars....more